Abstract:G protein-coupled receptors (GPCRs) have seven transmembrane spanning domains and comprise the largest superfamily with ~800 receptors in humans. GPCRs are attractive targets for drug discovery because they transduce intracellular signaling in response to endogenous ligands via heterotrimeric G proteins or arrestins, resulting in a wide variety of physiological and pathophysiological responses. The endogenous ligands for GPCRs are highly chemically diverse and include ions, biogenic amines, nucleotides, peptides, and lipids. In this review, we follow the KonMari method to better understand druggable lipid GPCRs. First, we have a comprehensive tidying up of lipid GPCRs including receptors for prostanoids, leukotrienes, specialized pro-resolving mediators (SPMs), lysophospholipids, sphingosine 1-phosphate (S1P), cannabinoids, platelet-activating factor (PAF), free fatty acids (FFAs), and sterols. This tidying up consolidates 46 lipid GPCRs and declutters several perplexing lipid GPCRs. Then, we further tidy up the lipid GPCR-directed drugs from the literature and databases, which identified 24 clinical drugs targeting 16 unique lipid GPCRs available in the market and 44 drugs under evaluation in more than 100 clinical trials as of 2019. Finally, we introduce drug designs for GPCRs that spark joy, such as positive or negative allosteric modulators (PAM or NAM), biased agonism, functional antagonism like fingolimod, and monoclonal antibodies (MAbs). These strategic drug designs may increase the efficacy and specificity of drugs and reduce side effects. Technological advances will help to discover more endogenous lipid ligands from the vast number of remaining orphan GPCRs and will also lead to the development novel lipid GPCR drugs to treat various diseases.

Allosteric Binding Sites at the Receptor–lipid Bilayer Interface: Novel Targets for GPCR Drug Discovery

Pharmacologically Targeting Intracellular Allosteric Sites of GPCRs for Drug Discovery.

Recent Advances in the Drug Discovery and Development of Dualsteric/ Bitopic Activators of G Protein-Coupled Receptors.

G protein-coupled receptors (GPCRs): advances in structures, mechanisms, and drug discovery

Small Molecule Allosteric Modulators of G-Protein-Coupled Receptors: Drug-Target Interactions.

Comparative Study of Allosteric GPCR Binding Sites and Their Ligandability Potential

Druggable Lipid GPCRs: Past, Present, and Prospects

Discovery of hidden allosteric sites as novel targets for allosteric drug design.

Is there a common allosteric binding site for G-protein coupled receptors?

Ligand binding at the protein–lipid interface: strategic considerations for drug design

Allosteric ligands control the activation of a class C GPCR heterodimer by acting at the transmembrane interface

Discovery of GPCR ligands for probing signal transduction pathways

Computational Tools for Allosteric Drug Discovery: Site Identification and Focus Library Design

Exploring Druggable Binding Sites on the Class A GPCRs Using the Residue Interaction Network and Site Identification by Ligand Competitive Saturation

Structural insights into positive and negative allosteric regulation of a G protein-coupled receptor through protein-lipid interactions

The therapeutic potential of allosteric ligands for free fatty acid sensitive GPCRs

Intercellular Lipid Mediators and GPCR Drug Discovery

Structure, function and drug discovery of GPCR signaling

Recent Advances in Structure, Function, and Pharmacology of Class A Lipid GPCRs: Opportunities and Challenges for Drug Discovery

Pharmacological Development of G Protein-Coupled Receptors Allosteric Modulation

Activation Pathway of a G Protein-Coupled Receptor Uncovers Conformational Intermediates As Targets for Allosteric Drug Design